Alcon has signed a licensing deal with Potentia Pharmaceuticals to...

Alcon has signed a licensing deal with Potentia Pharmaceuticals to develop that company's POT-4 drug to treat age-related macular degeneration. If Alcon decides to continue development of the drug, a separate agreement will allow it to buy the share of Potentia at certain conditions. Alcon will pay royalties to Potentia's ...

Keep reading this article by becoming a member

barrier_image_OIC

Enjoy unrestricted access to Eyewear Intelligence

To continue reading this article subscribe now

  • Unlimited access to our highly trusted industry insights and analysis
  • Benchmark yourself against the market and competitors
  • Find inspiration to drive your business forward
  • Stay up to date with new business models and startups

If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.